Chroma Medicine’s investigational one-time treatment CRMA-1001 for chronic hepatitis B brought levels of a key hepatitis B virus (HBV)…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
ALAGILLE SYNDROME
NewsLiver disorder most common Alagille symptom in children
Cholestasis, where the flow of the digestive fluid bile from the liver to the intestines slows or stalls, is…
CHOLANGITIS
NewsTriple treatment combo works best for UDCA-resistant PBC: Study
A triple treatment combination adding fibrates — a type of medication that has shown promise in primary biliary cholangitis…
BILIARY ATRESIA
NewsStudy identifies predictor of serious liver complication in biliary atresia
Having persistently high blood levels of bilirubin, a marker of liver damage, a year after undergoing a corrective liver surgery…
HEPATITIS
NewsWHO prequalifies 1st home test for hepatitis C
The World Health Organization (WHO) has prequalified the first self-test kit to detect the hepatitis C virus (HCV)…
CHOLESTASIS
NewsLivmarli now approved in EU to treat adults, children with PFIC
Livmarli (maralixibat), an oral medication from Mirum Pharmaceuticals, is now approved in the European Union to treat progressive…
FATTY LIVER DISEASE
NewsFerroptosis, type of cell death, may be therapeutic target for MASLD
A type of cell death called ferroptosis contributes to metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty…
CHOLESTASIS
NewsMaternal jaundice in ICP tied to worse pregnancy outcomes: Study
Women who develop a subtype of intrahepatic cholestasis of pregnancy (ICP) marked by jaundice — a yellowing of the…
ALAGILLE SYNDROME
NewsLivmarli sustains benefit for Alagille patients over 7 years: Trial data
Nearly all children with Alagille syndrome who received Mirum Pharmaceuticals’ Livmarli (maralixibat) for seven years as part of…
FATTY LIVER DISEASE
NewsIn NASH, VK2809 treatment reduces liver fat, fibrosis: Phase 2b trial
One year of treatment with Viking Therapeutics’ candidate VK2809 safely and effectively reduces liver fat content, damage, and scarring…